CL2018000933A1 - Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015). - Google Patents

Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Info

Publication number
CL2018000933A1
CL2018000933A1 CL2018000933A CL2018000933A CL2018000933A1 CL 2018000933 A1 CL2018000933 A1 CL 2018000933A1 CL 2018000933 A CL2018000933 A CL 2018000933A CL 2018000933 A CL2018000933 A CL 2018000933A CL 2018000933 A1 CL2018000933 A1 CL 2018000933A1
Authority
CL
Chile
Prior art keywords
strong
excipients
stabilizers
pharmaceutically acceptable
csf
Prior art date
Application number
CL2018000933A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CL2018000933A1 publication Critical patent/CL2018000933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>Una Composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrófagos (anti-GM-CSF) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, donde los vehículos, excipientes o estabilizadores farmacéuticamente aceptables son un regulador que es histidina; un azúcar que es sorbitol; y un tensoactivo no iónico que es TWEEN-80, donde dicho anticuerpo anti-GM-CSF comprende un péptido de cadena pesada variable (donde las CDRs están en negrillas y subrayadas): QVQLVESGGGLVQPGGSLRLSCAAS<u><strong>GFTFSSYWMN</strong></u>WVRQAPGKGLEWVS<strong><u>GIENKYAGGATYYA ASVKG</u></strong>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u><strong>GFGTDF</strong></u>WGQGTLVTVSS; y un péptido de cadena liviana variable ( donde las CDRs estan en negrillas y subrayadas): DlELTQPPSVSVAPGQTARISC<strong><u>SGDSIGKKYAY</u></strong>WYQQKPGQAPVLVIY<strong><u>KKRPS</u></strong>GIPERFSGSNSGN TATLTISGTQAEDEADYYC<strong><u>SAWGDKGM</u></strong>VFGGGTKLTVLGQ. </p>
CL2018000933A 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015). CL2018000933A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
CL2018000933A1 true CL2018000933A1 (es) 2018-07-20

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000696A CL2015000696A1 (es) 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide
CL2018000933A CL2018000933A1 (es) 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000696A CL2015000696A1 (es) 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide

Country Status (22)

Country Link
US (4) US20150246969A1 (es)
EP (3) EP3345923A1 (es)
JP (4) JP2015533806A (es)
KR (4) KR20150056846A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX382937B (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG10201803778PA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345923A1 (en) * 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
US10745475B2 (en) * 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
EP3139960B1 (en) * 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
MX2019003019A (es) 2016-09-19 2019-09-19 I Mab Anticuerpos anti-gm-csf y usos de los mismos.
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU4344697A (en) 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2137325A1 (en) * 2007-04-02 2009-12-30 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
PL2142174T3 (pl) 2007-04-05 2011-08-31 Sandoz Ag Stabilne wodne preparaty G-CSF
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091420A1 (es) * 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
RU2630969C2 (ru) * 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
HUE039788T2 (hu) 2009-12-31 2019-02-28 Arven Ilac Sanayi Ve Ticaret As Új eljárás G-CSF (granulocita kolónia stimuláló faktor) elõállítására
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
EP2729498A1 (en) 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
EP3345923A1 (en) * 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody

Also Published As

Publication number Publication date
JP2024156992A (ja) 2024-11-06
PH12015500591B1 (en) 2015-05-11
MX382937B (es) 2025-03-13
KR20230041086A (ko) 2023-03-23
US20150246969A1 (en) 2015-09-03
US10913792B2 (en) 2021-02-09
EA201590359A1 (ru) 2015-08-31
MA37946A1 (fr) 2018-01-31
CN104995210A (zh) 2015-10-21
IL237554B (en) 2019-12-31
EP3345923A1 (en) 2018-07-11
AU2013320261A1 (en) 2015-04-09
EP3916013A1 (en) 2021-12-01
PE20151079A1 (es) 2015-08-07
HK1208231A1 (en) 2016-02-26
MA37946B1 (fr) 2018-09-28
IL237554A0 (en) 2015-04-30
JP2015533806A (ja) 2015-11-26
UA117228C2 (uk) 2018-07-10
SG10201803778PA (en) 2018-06-28
CA2884124A1 (en) 2014-03-27
EA031489B1 (ru) 2019-01-31
CR20150153A (es) 2015-09-14
MX2015003644A (es) 2015-09-25
BR112015006189B1 (pt) 2022-04-05
WO2014044768A1 (en) 2014-03-27
KR20220028177A (ko) 2022-03-08
KR20150056846A (ko) 2015-05-27
CL2015000696A1 (es) 2015-10-23
MX2021006111A (es) 2021-07-07
IN2015KN00657A (es) 2015-07-17
US20180230208A1 (en) 2018-08-16
DOP2015000070A (es) 2015-08-16
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
EP2897977A1 (en) 2015-07-29
AU2016250388B2 (en) 2018-07-19
PH12015500591A1 (en) 2015-05-11
JP2022169709A (ja) 2022-11-09
KR20240091288A (ko) 2024-06-21
BR112015006189A2 (pt) 2019-11-26
US20210130451A1 (en) 2021-05-06
US20240417455A1 (en) 2024-12-19
JP2018138551A (ja) 2018-09-06
CN109999195A (zh) 2019-07-12
AU2016250388A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
CL2018000933A1 (es) Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).
AR132864A2 (es) UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
AR128047A2 (es) Moléculas de anticuerpos que se unen a il-17a e il-17f
CL2020001579A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145)
AR077595A1 (es) Tratamientos de combinacion
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
PE20142407A1 (es) Formulacion de anticuerpos
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20141537A1 (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos
PE20161390A1 (es) Anticuerpos multiespecificos
PE20150002A1 (es) Anticuerpos anti-fcrn
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
AR084315A1 (es) Anticuerpos anti-notch1
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
PE20170900A1 (es) Metodos y formulaciones para tratar enfermedades vasculares de los ojos
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
PE20142046A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma